The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -16.86 — distress zone — historically elevated failure riskWatch
- Earnings quality 63/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Pyxis Oncology, Inc. reports it. History and quarterly detail are in the app.
- Sale Of Royalty Rights$11.0M
- Milestone Revenue$2.8M
Leadership changes
From Pyxis Oncology, Inc.'s own filings, the day they're filed.
- Tom Civik · Chief Executive Officer · appointmenteff. 2026-02-02
- Jitendra Wadhane · Principal Financial Officer ("PFO") · appointmenteff. 2025-07-01
- Pamela Connealy · Chief Financial Officer · departureeff. 2025-07-01
Latest filings
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-07-02
- 8-K · Company announcement2026-06-15
- 8-K · Company announcement2026-05-14
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Pyxis Oncology, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Pyxis Oncology, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.